Aktie IVCPU SWIFTMERGE ACQUISITION CORP.
Zu einer Liste hinzufügen
Um diese Funktionalität nutzen zu können, müssen Sie Mitglied sein
EinloggenRegistrieren

Andere Sprachen Swiftmerge Acquisition Corp. Nasdaq

Aktien

IVCPU

KYG638361298

IVCPU

Markt geschlossen - Nasdaq
Andere Börsenplätze
 22:30:00 18.04.2024 		% 5 Tage % 1. Jan.
10,33 USD +1,67 % Intraday Chart für Swiftmerge Acquisition Corp. 0,00 % -3,64 %
01.04. Swiftmerge Acquisition Corp. meldet Ergebnis für das am 31. Dezember 2023 endende Geschäftsjahr CI
2023 Swiftmerge Acquisition Corp. meldet Ergebnis für das dritte Quartal und die neun Monate bis zum 30. September 2023 CI

Andere Sprachen

Suchen
Ergebnisse ansehen
Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!
100% kostenlose Registrierung
Swiftmerge Acquisition Corp. Reports Earnings Results for the Full Year Ended December 31, 2023
Swiftmerge Acquisition Corp. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
Swiftmerge Acquisition Corp. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023
Swiftmerge Acquisition : Non-Reliance on Previously Issued Financial Statements or Related Audit Report or Completed Interim Report - Form 8-K
Swiftmerge Acquisition Signs Merger Deal to Take HDL Therapeutics Public
HDL Therapeutics to Go Public in Merger with Swiftmerge Acquisition Corp.
SWIFTMERGE ACQUISITION CORP. : Entry into a Material Definitive Agreement, Amendments to Articles of Inc. or Bylaws; Change in Fiscal Year, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits (form 8-K)
Swiftmerge Acquisition : Adjournment of Extraordinary General Meeting - Form 8-K
Swiftmerge Acquisition Corp. Reports Earnings Results for the First Quarter Ended March 31, 2023
SWIFTMERGE ACQUISITION CORP. : Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Regulation FD Disclosure, Financial Statements and Exhibits (form 8-K)
HDL Therapeutics Inc Plans to Become Publicly Traded via a Business Combination With $225 Million Swiftmerge (NASDAQ: IVCP) With Goal to Transform Cardiovascular Disease Treatment
HDL Therapeutics, Inc. signed a non-binding letter of intent to acquire Swiftmerge Acquisition Corp. in a reverse merger transaction.
SWIFTMERGE ACQUISITION CORP. : Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Regulation FD Disclosure, Financial Statements and Exhibits (form 8-K)
SWIFTMERGE ACQUISITION CORP. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS (form 10-K)
Swiftmerge Acquisition Corp. Reports Earnings Results for the Full Year Ended December 31, 2022
Swiftmerge Acquisition Corp. Auditor Raises 'Going Concern' Doubt
Swiftmerge Acquisition Corp. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022
SWIFTMERGE ACQUISITION CORP. Management's Discussion and Analysis of Financial Condition and Results of Operations. (form 10-Q)
SWIFTMERGE ACQUISITION CORP. Management's Discussion and Analysis of Financial Condition and Results of Operations. (form 10-Q)
Swiftmerge Acquisition Corp. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022
Keine Ergebnisse zu dieser Suche
Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Filter

Suchen

Datum der Veröffentlichung

Vom

Bis

  1. Börse
  2. Aktien
  3. A3DRXV Aktie
  4. IVCPU Aktie
  5. Nachrichten Swiftmerge Acquisition Corp.
  6. Andere Sprachen